Literature DB >> 15767711

Effect of deferiprone on urinary zinc excretion in multiply transfused children with thalassemia major.

Sandip Bartakke1, S B Bavdekar, Pratima Kondurkar, Mamta N Muranjan, Mamata V Manglani, Ratna Sharma.   

Abstract

A prospective multi-centric study was conducted to determine if iron-chelating agent deferiprone also chelates zinc. Twenty four-hour urinary zinc levels were compared in multiply transfused children with thalassemia major not receiving any chelation therapy (Group A, n = 28), those receiving deferiprone (Group B, n = 30) and age and sex-matched controls of subjects in Group B (Group C, n = 29) by a colorimetric method. The 24-hour mean urinary excretion of zinc was significantly higher in Group B than in the other two groups indicating that deferiprone chelates zinc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15767711

Source DB:  PubMed          Journal:  Indian Pediatr        ISSN: 0019-6061            Impact factor:   1.411


  3 in total

1.  Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia.

Authors:  Saumya S Jamuar; Angeline H M Lai
Journal:  Ther Adv Hematol       Date:  2012-10

2.  Evaluating the Role of Zinc in Beta Thalassemia Major: A Prospective Case-Control Study from a Tertiary Care Teaching Hospital in India.

Authors:  Sujana Nidumuru; Venugopal Boddula; Sabitha Vadakedath; Bhagavan Reddy Kolanu; Venkataramana Kandi
Journal:  Cureus       Date:  2017-07-20

Review 3.  The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia.

Authors:  George J Kontoghiorghes; Marios Kleanthous; Christina N Kontoghiorghe
Journal:  Mediterr J Hematol Infect Dis       Date:  2020-01-01       Impact factor: 2.576

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.